Argenx Se (ARGX) Research & Development (2016 - 2026)
Argenx Se's (ARGX) quarterly Research & Development came in at -$486.0 million in Q2 2026, down 48.31% on a YoY basis from -$940.2 million in Q2 2025, and down 9.71% quarter-over-quarter from -$443.0 million in Q1 2026.
Powered by 
Analysis
Argenx Se (ARGX) Research & Development (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has reported Research & Development for 11 consecutive years, with -$486.0 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Research & Development fell 48.31% year-over-year to -$486.0 million; the trailing twelve-month figure through Jun 2026 stood at -$1.7 billion (down 41.34% YoY), and the FY2025 full-year result was -$1.4 billion, down 38.71% from the prior year.
- Research & Development slipped to -$486.0 million in Q2 2026 per ARGX's latest filing, from -$443.0 million in the prior quarter.
- Across five years, Research & Development topped out at -$126.9 million in Q2 2022 and bottomed at -$486.0 million in Q2 2026.
- Historically, Research & Development has averaged -$266.7 million across 5 years, with a median of -$236.3 million in 2022.
- The widest YoY moves for Research & Development: up 18.98% in 2023, down 107.29% in 2023.
- Over 5 years, Research & Development stood at -$147.8 million in 2022, then plunged by 107.29% to -$306.4 million in 2023, then grew by 2.98% to -$297.2 million in 2024, then dropped by 25.06% to -$371.7 million in 2025, then sank by 30.75% to -$486.0 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered -$486.0 million, -$443.0 million, and -$371.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Argenx Se | 58.53 Bn | 53.35 Bn | 1.37 Bn | -486.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -486.00 Mn |
| Mar 31, 2026 | -443.00 Mn |
| Dec 31, 2025 | -371.71 Mn |
| Sep 30, 2025 | -355.65 Mn |
| Jun 30, 2025 | -327.70 Mn |
| Mar 31, 2025 | -311.00 Mn |
| Dec 31, 2024 | -297.23 Mn |
| Sep 30, 2024 | -235.94 Mn |
| Jun 30, 2024 | -225.29 Mn |
| Mar 31, 2024 | -224.97 Mn |
| Dec 31, 2023 | -306.37 Mn |
| Sep 30, 2023 | -191.76 Mn |
| Jun 30, 2023 | -195.51 Mn |
| Mar 31, 2023 | -165.86 Mn |
| Dec 31, 2022 | -147.80 Mn |
| Sep 30, 2022 | -236.68 Mn |
| Jun 30, 2022 | -126.92 Mn |
| Mar 31, 2022 | -151.97 Mn |
| Dec 31, 2021 | -167.17 Mn |
| Sep 30, 2021 | -139.44 Mn |
API Access
Argenx Se Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=ARGX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "ARGX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=ARGX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();